Press release
Alzheimer's disease Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | AriBio Co., Ltd., Eli Lilly & Co., Cognition Therapeutics, AbbVie Inc., Allyx Therapeutics, Inc.
Alzheimer's disease Pipeline Insights, DelveInsight
Alzheimer's disease Overview:
Alzheimer's disease (AD) is a condition that leads to the deterioration of brain cells and is the primary cause of dementia, which results in cognitive decline and a loss of independence in daily activities. AD is considered a complex disease with multiple contributing factors. Two main theories have been proposed to explain its development: the cholinergic hypothesis and the amyloid hypothesis. Additionally, various risk factors-including aging, genetic predisposition, head trauma, vascular conditions, infections, and environmental influences-contribute to the onset and progression of the disease.
AD is characterized by two types of neuropathological changes that help explain disease progression and symptoms. The first type includes **positive lesions**, which result from accumulations of neurofibrillary tangles, amyloid plaques, dystrophic neurites, neuropil threads, and other deposits in the brain. The second type consists of **negative lesions**, which involve significant brain atrophy due to the loss of neurons, synapses, and neuropil. Furthermore, additional mechanisms, such as neuroinflammation, oxidative stress, and damage to cholinergic neurons, contribute to neurodegeneration.
The symptoms of AD vary based on the disease stage. It is categorized into three phases: preclinical (or presymptomatic), mild, and dementia-stage, which differ from the DSM-5 classification of AD. The earliest and most prevalent symptom is episodic short-term memory loss, while long-term memory remains relatively intact in the beginning. Even if not the primary complaint, short-term memory impairment is typically detectable in most patients. As the disease progresses, individuals experience difficulties with problem-solving, judgment, executive functions, motivation, organization, multitasking, and abstract thinking. Executive function impairments range from mild to severe in the early stages, followed by language difficulties and visuospatial deficits.
In the middle and later stages, neuropsychiatric symptoms such as apathy, social withdrawal, agitation, disinhibition, psychosis, and wandering often emerge. Over time, patients may develop dyspraxia (difficulty performing learned motor tasks), olfactory dysfunction, sleep disturbances, and extrapyramidal symptoms such as dystonia, akathisia, and Parkinsonian-like features. In the final stages, primitive reflexes return, incontinence occurs, and patients become entirely dependent on caregivers for daily needs.
Request for a detailed insights report on Alzheimer's disease pipeline insights @ https://www.delveinsight.com/report-store/alzheimers-disease-ad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
"Alzheimer's disease Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Alzheimer's disease Therapeutics Market.
Key Takeaways from the Alzheimer's disease Pipeline Report
DelveInsight's Alzheimer's disease pipeline report depicts a robust space with 110+ active players working to develop 120+ pipeline therapies for Alzheimer's disease treatment.
Key Alzheimer's disease companies such as AriBio Co., Ltd., Eli Lilly & Co., Cognition Therapeutics, AbbVie Inc., Allyx Therapeutics, Inc., Cassava Sciences, BioVie Inc., Novo Nordisk, Alector Inc., Longeveron Inc., Cognition Therapeutics, TrueBinding, Inc., VT BIO, Luye Pharma Group Ltd., Lexeo Therapeutics, Merck Sharp & Dohme LLC, Regeneration Biomedical, Alnylam Pharmaceuticals, Sinotau Pharmaceutical Group, Eisai Inc., Shanghai Hengrui Pharmaceutical Co., Ltd., and others are evaluating new drugs for Alzheimer's disease to improve the treatment landscape.
Promising Alzheimer's disease pipeline therapies in various stages of development include AR1001, NE3107, LY3372689, CT1812, ABBV-916, ALX-001, and others.
Recent breakthroughs in the Alzheimer's disease Pipeline Segment:
In January 2023, the U.S. Food and Drug Administration (FDA) granted accelerated approval for Leqembi, an amyloid beta-directed antibody targeting the underlying pathology of Alzheimer's disease by reducing amyloid plaques in the brain. This approval was based on early evidence suggesting potential clinical benefits.
In July 2023, the FDA converted Leqembi's status to traditional approval after a confirmatory Phase 3 clinical trial demonstrated its efficacy in slowing cognitive decline in patients with mild cognitive impairment or mild dementia due to AD.
Alzheimer's disease Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Alzheimer's disease Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Alzheimer's disease treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Alzheimer's disease market.
Download our free sample page report on Alzheimer's disease pipeline insights @ https://www.delveinsight.com/sample-request/alzheimers-disease-ad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Alzheimer's disease Emerging Drugs
AR1001: AriBio Co., Ltd.
NE3107: BioVie
LY3372689: Eli Lilly & Co.
CT1812: Cognition Therapeutics
ABBV-916: AbbVie Inc.
ALX-001: Allyx Therapeutics, Inc.
Alzheimer's disease Companies
Around 110 companies are actively working on developing therapies for Alzheimer's disease. Among them, AriBio Co., Ltd. and BioVie have drug candidates that have reached the most advanced stage of development, Phase III clinical trials.
DelveInsight's report covers around 120+ products under different phases of clinical development like
Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Alzheimer's disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Intravenous
Subcutaneous
Oral
Intramuscular
Alzheimer's disease Products have been categorized under various Molecule types such as
Monoclonal antibody
Small molecule
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Alzheimer's disease Therapies and Key Companies: Alzheimer's disease Clinical Trials and advancements @ https://www.delveinsight.com/report-store/alzheimers-disease-ad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Alzheimer's disease Pipeline Therapeutic Assessment
• Alzheimer's disease Assessment by Product Type
• Alzheimer's disease By Stage
• Alzheimer's disease Assessment by Route of Administration
• Alzheimer's disease Assessment by Molecule Type
Download Alzheimer's disease Sample report to know in detail about the Alzheimer's disease treatment market @ Alzheimer's disease Therapeutic Assessment @ https://www.delveinsight.com/sample-request/alzheimers-disease-ad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Table of Content
1. Report Introduction
2. Executive Summary
3. Alzheimer's disease Current Treatment Patterns
4. Alzheimer's disease - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Alzheimer's disease Late-Stage Products (Phase-III)
7. Alzheimer's disease Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Alzheimer's disease Discontinued Products
13. Alzheimer's disease Product Profiles
14. Alzheimer's disease Key Companies
15. Alzheimer's disease Key Products
16. Dormant and Discontinued Products
17. Alzheimer's disease Unmet Needs
18. Alzheimer's disease Future Perspectives
19. Alzheimer's disease Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Alzheimer's disease Pipeline Reports Offerings: https://www.delveinsight.com/report-store/alzheimers-disease-ad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Alzheimer's disease Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | AriBio Co., Ltd., Eli Lilly & Co., Cognition Therapeutics, AbbVie Inc., Allyx Therapeutics, Inc. here
News-ID: 3922322 • Views: …
More Releases from DelveInsight Business Research LLP
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market…
More Releases for Alzheimer
Dementia - Alzheimer Disease Market: A Comprehensive Analysis 2030
Dementia and Alzheimer's disease represent significant challenges within the global healthcare sector. These neurological disorders, characterized by progressive cognitive decline, have seen increasing prevalence due to aging populations worldwide. This growing burden has spurred interest in the Dementia - Alzheimer's disease market, encompassing diagnostic tools, treatments, caregiving solutions, and related healthcare services. This article provides an overview of the market, its scope, current trends, and factors driving its expansion.
Data Bridge…
Alzheimer Disease Treatment Market | Allergan, Amgen, Daiichi Sankyo, Eisai
The global alzheimer disease treatment market report is a comprehensive report that provides a detailed analysis of the current status and future trends of the alzheimer disease treatment market worldwide. This report provides valuable information to industry stakeholders by offering an in-depth perspective on market dynamics, competitive landscape, growth opportunities, and key challenges faced by industry participants.
From the perspective of market dynamics, this report explores the factors driving the growth…
United States Alzheimer Drugs Market Insights Deep Analysis 2023-2031
Cognate Life Sciences introduces a report on "United States Alzheimer Drugs Market 2023" with Market Insights Reports, Introduces systematic details in terms of market valuation, market size, revenue estimation, and geographical spectrum of the business vertical. The study also talks about crucial pockets of the industry such as products or services offered, downstream fields, end using customers, historic data figures regarding revenue and sales, market context and more. It conjointly…
Global Alzheimer Market, Global Alzheimer Industry, Covid-19 Impact Global Alzhe …
Alzheimer's is a progressive disease that leads to the death of brain cells, resulting in memory loss, behavioral issues, and disruption the thought processes. The Alzheimer disease is considered fatal. Age and heredity are the two main risk factors for developing Alzheimer's disease. Several other preventable risk factors have been associated to the development of this disease, including diet, environment, and overall general health. A combination of risk factors is…
US Alzheimer Drug Pipeline Analysis
In US, the Alzheimer's disease is the 6th leading cause of death overall and among those aged 65 and above, it is the 5th leading cause of death. While the deaths from major diseases, like heart disease have decreased, the death due to Alzheimer's have increased by more than 60% between 2000 and 2012. The total number of patients having Alzheimer’s disease was 5.4 million in 2012. Out of this,…
Global Alzheimer Market Report: 2015 Edition | Now Available at Researchmoz.us
Researchmoz added Most up-to-date research on "Global Alzheimer Market Report: 2015 Edition" to its huge collection of research reports.
Alzheimer’s disease is defined as an advanced neurological disorder that increasingly deprives patients of their memory and ability to carry out daily activities. As it grows in a human brain, individuals are likely to practice difficulties in linguistic, agility and insight along with negative changes in the character and performance such as…
